The root cause needs to be addressed through nutrition and supplementation rather than injection scheduling
In the fourth quarter of 2024, GLP-1 sales accounted for 30% of Himss $481 million in total revenue, and it was estimated that Hims was responsible for 20% of all compounded GLP-1 prescriptions in the US during that period
It is the active ingredient in Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for weight management)
Regulatory submissions are in progress, but approval timelines are uncertain, likely 2026-2028 at earliest for major markets
[DOI] [PubMed] [Google Scholar] 39.Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., Probstfield J., Riesmeyer J.S., Riddle M.C., Rydn L., et al
They may recommend adjusting your semaglutide dosage or tirzepatide dosage or potentially changing the medication